Antihormonal Cancer Therapies Market, Global Outlook and Forecast 2022-2028

April 2022 | 65 pages | ID: AAE4BD7A9742EN
Market Monitor Global

Abstracts

Antihormonal Cancer Therapy is a treatment with drugs, surgery, or radiation in order to block the production or action of a hormone. Antihormone therapy may be used in cancer treatment because certain hormones are able to stimulate the growth of some types of tumors.

This report contains market size and forecasts of Antihormonal Cancer Therapies in Global, including the following market information:

Global Antihormonal Cancer Therapies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Antihormonal Cancer Therapies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Radiations Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antihormonal Cancer Therapies include AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals and Tolmar, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihormonal Cancer Therapies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antihormonal Cancer Therapies Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Antihormonal Cancer Therapies Market Segment Percentages, by Type, 2021 (%)

• Radiations
• Drugs
• Surgeries
• Others

Global Antihormonal Cancer Therapies Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Antihormonal Cancer Therapies Market Segment Percentages, by Application, 2021 (%)

• Breast Cancer
• Prostate Cancer
• Other

Global Antihormonal Cancer Therapies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Antihormonal Cancer Therapies Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antihormonal Cancer Therapies revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Antihormonal Cancer Therapies revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AstraZeneca
• Novartis
• Pfizer
• Sanofi
• Takeda
• Roche
• Amgen
• Samyang Biopharmaceuticals
• Tolmar
• Bluebird Bio
• Bristol-Myers Squibb
• Exelixis
• Guardant Health
• Illumina

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Antihormonal Cancer Therapies Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Antihormonal Cancer Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTIHORMONAL CANCER THERAPIES OVERALL MARKET SIZE

2.1 Global Antihormonal Cancer Therapies Market Size: 2021 VS 2028
2.2 Global Antihormonal Cancer Therapies Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Antihormonal Cancer Therapies Players in Global Market
3.2 Top Global Antihormonal Cancer Therapies Companies Ranked by Revenue
3.3 Global Antihormonal Cancer Therapies Revenue by Companies
3.4 Top 3 and Top 5 Antihormonal Cancer Therapies Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antihormonal Cancer Therapies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antihormonal Cancer Therapies Players in Global Market
  3.6.1 List of Global Tier 1 Antihormonal Cancer Therapies Companies
  3.6.2 List of Global Tier 2 and Tier 3 Antihormonal Cancer Therapies Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Antihormonal Cancer Therapies Market Size Markets, 2021 & 2028
  4.1.2 Radiations
  4.1.3 Drugs
  4.1.4 Surgeries
  4.1.5 Others
4.2 By Type - Global Antihormonal Cancer Therapies Revenue & Forecasts
  4.2.1 By Type - Global Antihormonal Cancer Therapies Revenue, 2017-2022
  4.2.2 By Type - Global Antihormonal Cancer Therapies Revenue, 2023-2028
  4.2.3 By Type - Global Antihormonal Cancer Therapies Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Antihormonal Cancer Therapies Market Size, 2021 & 2028
  5.1.2 Breast Cancer
  5.1.3 Prostate Cancer
  5.1.4 Other
5.2 By Application - Global Antihormonal Cancer Therapies Revenue & Forecasts
  5.2.1 By Application - Global Antihormonal Cancer Therapies Revenue, 2017-2022
  5.2.2 By Application - Global Antihormonal Cancer Therapies Revenue, 2023-2028
  5.2.3 By Application - Global Antihormonal Cancer Therapies Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Antihormonal Cancer Therapies Market Size, 2021 & 2028
6.2 By Region - Global Antihormonal Cancer Therapies Revenue & Forecasts
  6.2.1 By Region - Global Antihormonal Cancer Therapies Revenue, 2017-2022
  6.2.2 By Region - Global Antihormonal Cancer Therapies Revenue, 2023-2028
  6.2.3 By Region - Global Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Antihormonal Cancer Therapies Revenue, 2017-2028
  6.3.2 US Antihormonal Cancer Therapies Market Size, 2017-2028
  6.3.3 Canada Antihormonal Cancer Therapies Market Size, 2017-2028
  6.3.4 Mexico Antihormonal Cancer Therapies Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Antihormonal Cancer Therapies Revenue, 2017-2028
  6.4.2 Germany Antihormonal Cancer Therapies Market Size, 2017-2028
  6.4.3 France Antihormonal Cancer Therapies Market Size, 2017-2028
  6.4.4 U.K. Antihormonal Cancer Therapies Market Size, 2017-2028
  6.4.5 Italy Antihormonal Cancer Therapies Market Size, 2017-2028
  6.4.6 Russia Antihormonal Cancer Therapies Market Size, 2017-2028
  6.4.7 Nordic Countries Antihormonal Cancer Therapies Market Size, 2017-2028
  6.4.8 Benelux Antihormonal Cancer Therapies Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Antihormonal Cancer Therapies Revenue, 2017-2028
  6.5.2 China Antihormonal Cancer Therapies Market Size, 2017-2028
  6.5.3 Japan Antihormonal Cancer Therapies Market Size, 2017-2028
  6.5.4 South Korea Antihormonal Cancer Therapies Market Size, 2017-2028
  6.5.5 Southeast Asia Antihormonal Cancer Therapies Market Size, 2017-2028
  6.5.6 India Antihormonal Cancer Therapies Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Antihormonal Cancer Therapies Revenue, 2017-2028
  6.6.2 Brazil Antihormonal Cancer Therapies Market Size, 2017-2028
  6.6.3 Argentina Antihormonal Cancer Therapies Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Antihormonal Cancer Therapies Revenue, 2017-2028
  6.7.2 Turkey Antihormonal Cancer Therapies Market Size, 2017-2028
  6.7.3 Israel Antihormonal Cancer Therapies Market Size, 2017-2028
  6.7.4 Saudi Arabia Antihormonal Cancer Therapies Market Size, 2017-2028
  6.7.5 UAE Antihormonal Cancer Therapies Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca
  7.1.1 AstraZeneca Corporate Summary
  7.1.2 AstraZeneca Business Overview
  7.1.3 AstraZeneca Antihormonal Cancer Therapies Major Product Offerings
  7.1.4 AstraZeneca Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.1.5 AstraZeneca Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Antihormonal Cancer Therapies Major Product Offerings
  7.2.4 Novartis Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.2.5 Novartis Key News
7.3 Pfizer
  7.3.1 Pfizer Corporate Summary
  7.3.2 Pfizer Business Overview
  7.3.3 Pfizer Antihormonal Cancer Therapies Major Product Offerings
  7.3.4 Pfizer Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.3.5 Pfizer Key News
7.4 Sanofi
  7.4.1 Sanofi Corporate Summary
  7.4.2 Sanofi Business Overview
  7.4.3 Sanofi Antihormonal Cancer Therapies Major Product Offerings
  7.4.4 Sanofi Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.4.5 Sanofi Key News
7.5 Takeda
  7.5.1 Takeda Corporate Summary
  7.5.2 Takeda Business Overview
  7.5.3 Takeda Antihormonal Cancer Therapies Major Product Offerings
  7.5.4 Takeda Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.5.5 Takeda Key News
7.6 Roche
  7.6.1 Roche Corporate Summary
  7.6.2 Roche Business Overview
  7.6.3 Roche Antihormonal Cancer Therapies Major Product Offerings
  7.6.4 Roche Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.6.5 Roche Key News
7.7 Amgen
  7.7.1 Amgen Corporate Summary
  7.7.2 Amgen Business Overview
  7.7.3 Amgen Antihormonal Cancer Therapies Major Product Offerings
  7.7.4 Amgen Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.7.5 Amgen Key News
7.8 Samyang Biopharmaceuticals
  7.8.1 Samyang Biopharmaceuticals Corporate Summary
  7.8.2 Samyang Biopharmaceuticals Business Overview
  7.8.3 Samyang Biopharmaceuticals Antihormonal Cancer Therapies Major Product Offerings
  7.8.4 Samyang Biopharmaceuticals Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.8.5 Samyang Biopharmaceuticals Key News
7.9 Tolmar
  7.9.1 Tolmar Corporate Summary
  7.9.2 Tolmar Business Overview
  7.9.3 Tolmar Antihormonal Cancer Therapies Major Product Offerings
  7.9.4 Tolmar Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.9.5 Tolmar Key News
7.10 Bluebird Bio
  7.10.1 Bluebird Bio Corporate Summary
  7.10.2 Bluebird Bio Business Overview
  7.10.3 Bluebird Bio Antihormonal Cancer Therapies Major Product Offerings
  7.10.4 Bluebird Bio Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.10.5 Bluebird Bio Key News
7.11 Bristol-Myers Squibb
  7.11.1 Bristol-Myers Squibb Corporate Summary
  7.11.2 Bristol-Myers Squibb Business Overview
  7.11.3 Bristol-Myers Squibb Antihormonal Cancer Therapies Major Product Offerings
  7.11.4 Bristol-Myers Squibb Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.11.5 Bristol-Myers Squibb Key News
7.12 Exelixis
  7.12.1 Exelixis Corporate Summary
  7.12.2 Exelixis Business Overview
  7.12.3 Exelixis Antihormonal Cancer Therapies Major Product Offerings
  7.12.4 Exelixis Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.12.5 Exelixis Key News
7.13 Guardant Health
  7.13.1 Guardant Health Corporate Summary
  7.13.2 Guardant Health Business Overview
  7.13.3 Guardant Health Antihormonal Cancer Therapies Major Product Offerings
  7.13.4 Guardant Health Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.13.5 Guardant Health Key News
7.14 Illumina
  7.14.1 Illumina Corporate Summary
  7.14.2 Illumina Business Overview
  7.14.3 Illumina Antihormonal Cancer Therapies Major Product Offerings
  7.14.4 Illumina Antihormonal Cancer Therapies Revenue in Global Market (2017-2022)
  7.14.5 Illumina Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Antihormonal Cancer Therapies Market Opportunities & Trends in Global Market
Table 2. Antihormonal Cancer Therapies Market Drivers in Global Market
Table 3. Antihormonal Cancer Therapies Market Restraints in Global Market
Table 4. Key Players of Antihormonal Cancer Therapies in Global Market
Table 5. Top Antihormonal Cancer Therapies Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Antihormonal Cancer Therapies Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Antihormonal Cancer Therapies Revenue Share by Companies, 2017-2022
Table 8. Global Companies Antihormonal Cancer Therapies Product Type
Table 9. List of Global Tier 1 Antihormonal Cancer Therapies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antihormonal Cancer Therapies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Antihormonal Cancer Therapies Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Antihormonal Cancer Therapies Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Antihormonal Cancer Therapies Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Antihormonal Cancer Therapies Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Antihormonal Cancer Therapies Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Antihormonal Cancer Therapies Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Antihormonal Cancer Therapies Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Antihormonal Cancer Therapies Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Antihormonal Cancer Therapies Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Antihormonal Cancer Therapies Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Antihormonal Cancer Therapies Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Antihormonal Cancer Therapies Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Antihormonal Cancer Therapies Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Antihormonal Cancer Therapies Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Antihormonal Cancer Therapies Product Offerings
Table 32. AstraZeneca Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Antihormonal Cancer Therapies Product Offerings
Table 35. Novartis Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Antihormonal Cancer Therapies Product Offerings
Table 38. Pfizer Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 39. Sanofi Corporate Summary
Table 40. Sanofi Antihormonal Cancer Therapies Product Offerings
Table 41. Sanofi Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 42. Takeda Corporate Summary
Table 43. Takeda Antihormonal Cancer Therapies Product Offerings
Table 44. Takeda Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 45. Roche Corporate Summary
Table 46. Roche Antihormonal Cancer Therapies Product Offerings
Table 47. Roche Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 48. Amgen Corporate Summary
Table 49. Amgen Antihormonal Cancer Therapies Product Offerings
Table 50. Amgen Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 51. Samyang Biopharmaceuticals Corporate Summary
Table 52. Samyang Biopharmaceuticals Antihormonal Cancer Therapies Product Offerings
Table 53. Samyang Biopharmaceuticals Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 54. Tolmar Corporate Summary
Table 55. Tolmar Antihormonal Cancer Therapies Product Offerings
Table 56. Tolmar Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 57. Bluebird Bio Corporate Summary
Table 58. Bluebird Bio Antihormonal Cancer Therapies Product Offerings
Table 59. Bluebird Bio Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 60. Bristol-Myers Squibb Corporate Summary
Table 61. Bristol-Myers Squibb Antihormonal Cancer Therapies Product Offerings
Table 62. Bristol-Myers Squibb Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 63. Exelixis Corporate Summary
Table 64. Exelixis Antihormonal Cancer Therapies Product Offerings
Table 65. Exelixis Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 66. Guardant Health Corporate Summary
Table 67. Guardant Health Antihormonal Cancer Therapies Product Offerings
Table 68. Guardant Health Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)
Table 69. Illumina Corporate Summary
Table 70. Illumina Antihormonal Cancer Therapies Product Offerings
Table 71. Illumina Antihormonal Cancer Therapies Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Antihormonal Cancer Therapies Segment by Type in 2021
Figure 2. Antihormonal Cancer Therapies Segment by Application in 2021
Figure 3. Global Antihormonal Cancer Therapies Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Antihormonal Cancer Therapies Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Antihormonal Cancer Therapies Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Antihormonal Cancer Therapies Revenue in 2021
Figure 8. By Type - Global Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 9. By Application - Global Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 10. By Region - Global Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 11. By Country - North America Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 12. US Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 16. Germany Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 17. France Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 24. China Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 28. India Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 30. Brazil Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Antihormonal Cancer Therapies Revenue Market Share, 2017-2028
Figure 33. Turkey Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Antihormonal Cancer Therapies Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Sanofi Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Takeda Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Roche Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Amgen Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Samyang Biopharmaceuticals Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Tolmar Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bluebird Bio Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Bristol-Myers Squibb Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Exelixis Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Guardant Health Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Illumina Antihormonal Cancer Therapies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)